Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | MARS1 | P56192 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000521 | 0.90 | KMT2A (0.66) | KMT2AMEN1SMN1; SMN2PTGS2MALT1 | |
| SCHEMBL14622603 | 0.84 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2PTGS2MARS1 | |
| SCHEMBL28038235 | 0.81 | SMPD1 (0.67) | SMN1; SMN2SMPD1PTGS2MALT1 | |
| SCHEMBL3473773 | 0.80 | NR1H2 (0.61) | KMT2AMEN1SMN1; SMN2PTGS2 | |
| SCHEMBL27716914 | 0.79 | KMT2A (0.52) | KMT2AMEN1SMN1; SMN2SMPD1PTGS2 | |
| SCHEMBL4488941 | 0.76 | KMT2A (0.82) | KMT2AMEN1SMN1; SMN2FABP3SNCA | |
| SCHEMBL9643919 | 0.76 | MALT1 (0.73) | KMT2AMEN1SMN1; SMN2SMPD1MALT1 | |
| SCHEMBL4486680 | 0.76 | KMT2A (1.00) | KMT2AMEN1SMN1; SMN2MARS1 | |
| SCHEMBL17114573 | 0.75 | PTGS2 (0.58) | KMT2AMEN1PTGS2 | |
| SCHEMBL1514517 | 0.75 | KMT2A (0.81) | KMT2AMEN1SMN1; SMN2MALT1MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | KMT2A 2663/4885MEN1 3666/4885SMN1; SMN2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.